After H.C. Wainwright and Cantor Fitzgerald gave Menlo Therapeutics (NASDAQ: MNLO) a Buy rating last month, the company received another Buy, this time from Northland Securities. Analyst Tim Chiang maintained a Buy rating on Menlo Therapeutics today and set a price target of $6.00. The company’s shares closed last Friday at $2.39.
According to TipRanks.com, Chiang is a 2-star analyst with an average return of 0.5% and a 49.5% success rate. Chiang covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Pacira Pharmaceuticals, and BioDelivery.
Currently, the analyst consensus on Menlo Therapeutics is a Strong Buy with an average price target of $6.93, which is a 166.5% upside from current levels. In a report issued on May 29, Cantor Fitzgerald also maintained a Buy rating on the stock with a $15.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $7.48 and a one-year low of $1.00. Currently, Menlo Therapeutics has an average volume of 3.4M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Menlo Therapeutics Inc. operates as biopharmaceutical company which is focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. The company was founded in October, 2011 and is headquartered in Redwood City, CA.
Read More on MNLO:
